StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.04+0.03 (+2.97%)

Close on Nov 18, 2026Market cap $13.87MP/E –Yield 0.00%

Tvardi Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tvardi Therapeutics's revenue for the twelve months ending Mar 31, 2025 was $7.57M, down 55.3% year over year. For fiscal 2024 it was $7.14M, down 66.0% from the year before. Over ten years it grew 8.4% a year on average. The highest annual figure on record is $135.08M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$7.14M-66.0%
FY2023Dec 31, 2023$20.97M-49.9%
FY2022Dec 31, 2022$41.87M+81.8%
FY2021Dec 31, 2021$23.03M-83.0%
FY2020Dec 31, 2020$135.08M+579.3%
FY2019Dec 31, 2019$19.89M+47.6%
FY2018Dec 31, 2018$13.47M+1378.5%
FY2017Dec 31, 2017$911.00K+959.3%
FY2016Dec 31, 2016$86.00K-97.7%
FY2015Dec 31, 2015$3.80M+19.7%
FY2014Dec 31, 2014$3.18M-73.4%
FY2013Dec 31, 2013$11.96M+905.4%
FY2012Dec 31, 2012$1.19M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025$2.57M+20.3%
Q4 FY2024Dec 31, 2024$1.46M-51.6%
Q3 FY2024Sep 30, 2024$2.56M-47.5%
Q2 FY2024Jun 30, 2024$991.00K-85.7%
Q1 FY2024Mar 31, 2024$2.14M-65.4%
Q4 FY2023Dec 31, 2023$3.00M-7.9%
Q3 FY2023Sep 30, 2023$4.87M-55.0%
Q2 FY2023Jun 30, 2023$6.93M-69.9%
Q1 FY2023Mar 31, 2023$6.17M+28.7%
Q4 FY2022Dec 31, 2022$3.26M+297.2%
Q3 FY2022Sep 30, 2022$10.81M-46.7%
Q2 FY2022Jun 30, 2022$23.00M–
Q1 FY2022Mar 31, 2022$4.79M+147.5%
Q4 FY2021Dec 31, 2021$821.00K-99.3%
Q3 FY2021Sep 30, 2021$20.27M+118.8%
Q2 FY2021Jun 30, 2021$0-100.0%
Q1 FY2021Mar 31, 2021$1.94M-76.1%
Q4 FY2020Dec 31, 2020$112.09M+2384.8%
Q3 FY2020Sep 30, 2020$9.27M+60.2%
Q2 FY2020Jun 30, 2020$5.63M+8.2%
Q1 FY2020Mar 31, 2020$8.09M+84.7%
Q4 FY2019Dec 31, 2019$4.51M-18.5%
Q3 FY2019Sep 30, 2019$5.79M+14.3%
Q2 FY2019Jun 30, 2019$5.21M+81.2%
Q1 FY2019Mar 31, 2019$4.38M–
Q4 FY2018Dec 31, 2018$5.53M–
Q3 FY2018Sep 30, 2018$5.06M–
Q2 FY2018Jun 30, 2018$2.87M+215.5%
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$911.00K–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–

More Tvardi Therapeutics figures

See a number that looks wrong?